Esolembic-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing effective relief from acid-related mucosal damage and promoting ulcer healing. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance by reducing dosing frequency. Esolembic-D Capsule SR is indicated for patients experiencing symptomatic GERD with delayed gastric emptying or those requiring acid suppression alongside prokinetic therapy. It should be administered as prescribed by a healthcare professional, with consideration for contraindications such as hypersensitivity to components or underlying cardiac conditions. Monitoring is advised during prolonged use to detect potential adverse effects, including cardiac arrhythmias associated with Domperidone. This combination offers a synergistic approach to managing complex upper gastrointestinal symptoms, improving patient quality of life through targeted pharmacological action.